Renee D. Gala Salary and Compensation - Jazz Pharmaceuticals plc CEO Pay 2025

In fiscal year 2025, Renee D. Gala, President CEO and Director of Jazz Pharmaceuticals plc (JAZZ), received total compensation of $19.2 million.

Renee D. Gala's compensation breakdown includes: base salary of $1.0 million, stock awards valued at $16.1 million, non-equity incentive compensation of $2.0 million, and other compensation of $30K.

Compared to fiscal year 2024, Renee D. Gala's total compensation increased 23% from $15.5 million to $19.2 million.

Jazz Pharmaceuticals plc (JAZZ) Executive Pay 2025

Jazz Pharmaceuticals plc's top 5 named executive officers received combined total compensation of $47.7 million in fiscal year 2025.

The named executive officers disclosed in Jazz Pharmaceuticals plc's 2025 proxy statement are:Renee D. Gala (President CEO and Director) with total compensation of $19.2 million, Robert Iannone (M.D., M.S.C.E Executive Vice President, Global Head of R&D) with total compensation of $8.7 million, Philip L. Johnson (Executive Vice President and CFO) with total compensation of $7.5 million, Neena M. Patil (Executive Vice President and Chief Legal Officer) with total compensation of $6.3 million, and Samantha Pearce (Executive Vice President Chief Commercial Officer) with total compensation of $6.1 million.